Bone marrow transplant for young patients with non-malignant disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness and safety of familial HLA mismatched bone marrow transplants in patients under 21 years old with non-malignant disorders. Participants will undergo a reduced intensity conditioning regimen followed by the transplant procedure. The primary goal is to assess donor cell engraftment and safety at 100 days and one year after the transplant. The study focuses on patients with severe manifestations of conditions like sickle cell disease, bone marrow failure syndromes, and other metabolic or immunologic disorders.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Nonmalignant disorder requiring bone marrow transplant including bone marrow failure syndromes, metabolic disorders, immunologic disorders, or hemoglobinopathy
* For patients with sickle cell disease, must have one of the following severe manifestations:

  1. Overt or silent stroke or persistently elevated transcranial doppler velocities despite transfusion therapy
  2. Recurrent acute chest syndrome with significant respiratory compromise each time
  3. Sickle nephropathy
  4. Recurrent admissions for vaso-occlusive episodes resulting in prolonged opioid use and poor quality of life with interrupted school attendance activity
  5. Red cell alloimmunization with the need for chronic transfusions
  6. Recurrent osteonecrosis or multiple joint involvement from avascular necrosis
* Patients with sickle cell disease must have hemoglobin S \< 30% within 30 days prior to beginning alemtuzumab
* Age \</= 20.99 years at the time of enrollment
* Performance score \>/= 50
* Left ventricular ejection fraction \> 40% or left ventricular shortening fraction \> 26% by echocardiogram
* DLCO \> 40% (corrected for hemoglobin) or pulse oximetry with a baseline O2 saturation of \>/= 90% on room air if too young to perform PFTs
* Serum creatinine \</= 1.5x upper limit of normal for age and/or GFR \> 70 mL/min/1.73m2
* Direct bilirubin \< 2x upper limit of normal for age
* ALT and AST \< 5x upper limit of normal for age
* Participants who have or are receiving \>/= 8 packed red blood cell transfusions for \>/= 1 year or \>/= 20 packed red blood cell transfusions (lifetime cumulative) will undergo liver MRI for estimation of hepatic iron content.

  1\. Liver biopsy is indicated for hepatic iron content \>/= 7mg Fe/mg liver dry weight by liver MRI. Histologic examination of the liver must document for the absence of cirrhosis, bridging fibrosis, and active hepatitis
* Female subjects of childbearing potential, must agree to practice 2 methods of contraception at the same time from the time of signing of informed consent through 12 months post transplant. Male subjects must agree to practice effective barrier contraception or practice true abstinence from the time of signing informed consent through 12 months post transplant.
* Written informed consent must be obtained from all recipients in accordance with the guidelines of the institution's Human Studies Committee.

Exclusion Criteria:

* Patients who have an HLA-identical sibling who is able and willing to donate bone marrow
* Patients with cirrhosis or established bridging fibrosis of the liver or active hepatitis
* Uncontrolled bacterial, viral, or fungal infection within 6 weeks prior to enrollment
* Evidence of HIV infection or known HIV positive serology
* Patients who have received a previous stem cell transplant
* Patients who have received an investigational drug or device or off-label use of a drug or device within 3 months of enrollment
* Females who are pregnant or breast feeding
* Patients with active autoimmune disease (e.g. sarcoidosis, lupus, scleroderma)

Where it's running

• Yale School of Medicine
  New Haven, Connecticut, United States Recruiting
• Nemours Children's Health
  Wilmington, Delaware, United States Recruiting
• Helen DeVos Children's Hospital
  Grand Rapids, Michigan, United States Recruiting
• Washington University School of Medicine
  St Louis, Missouri, United States Recruiting

Study contacts

• Principal investigator: Shalini Shenoy, MD — Washington University School of Medicine
• Study coordinator: Shalini Shenoy, MD
• Email: shalinishenoy@wustl.edu
• Phone: 314-454-6018

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Transplant conditioning for non-malignant diseases using immune suppression

  This study is testing a new way to prepare children with non-cancer diseases for a stem cell transplant to see if it helps their bodies accept the donor cells while causing fewer side effects.

  Recruiting Phase 1/2 Washington University School of Medicine · Phoenix, Arizona and 27 other locations · NCT00920972

• Dibotatug in adults with bone marrow failure syndromes

  This study tests dibotatug (DR-01) to see if it is safe and helps people with bone marrow failure syndromes like severe aplastic anemia who have not responded to standard therapies.

  Recruiting at 2 sites Phase 1/2 Dren Bio · Duarte, California and 9 other locations · NCT07712562

• Orforglipron for Type 2 Diabetes in Ramadan Fasters

  This study tests whether orforglipron helps people with type 2 diabetes who fast during Ramadan, to see if it improves blood sugar control safely.

  Recruiting at 33 sites Phase 3 Eli Lilly and Company · Agra and 39 other locations · NCT07613307

• Environmental and inflammatory links to metabolic and endocrine diseases

  This project will see if combining environmental, genetic, and protein information can help predict early risk of diabetes, hypertension, and other metabolic or endocrine problems in community adults.

  Recruiting Chongqing Medical University · Chongqing · NCT07512609

• How moderate wine drinking affects healthy aging through post-meal extracellular vesicles

  This test will see if a single serving of red or white wine changes circulating extracellular vesicles in healthy adults aged 35–65.

  Recruiting University of Seville · Seville, Sevilla · NCT07361887

• HOPE Biobank: connecting blood disease patients through stem cell transplant and gene therapy samples

  This study will collect blood and other biospecimens along with clinical data from people undergoing stem cell transplant or gene therapy for non-cancer blood diseases to build a large biobank for future research.

  Recruiting at 14 sites Medical College of Wisconsin · Duarte, California and 13 other locations · NCT07227155

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.